The following information is provided in accordance with Paragraph 9.25 of the Main Market Listing Requirements (MMLR) of Bursa Malaysia Securities Berhad (Bursa Securities), as set out in Part A of Appendix 9C thereto. Utilisation of Proceeds Save as disclosed below, there were no proceeds raised by the Company from corporate proposals during the financial year ended 31 December 2023 (FY2023): • On 31 March 2023, the Company completed the disposal of the entire issued ordinary share capital of IMU Health Sdn Bhd (IMUH) and its subsidiaries. The cash proceeds of approximately RM1.2 billion was utilised to partly fund the payment of the first and final single tier cash dividend of 7.0 sen per ordinary share for the financial year ended 31 December 2022 that was paid on 28 April 2023, and for the payment of the special cash dividend of 9.6 sen per ordinary share for the FY2023 that was paid on 30 June 2023. Employee Share Scheme The employee share scheme established by our Group and still in existence during FY2023 is Enterprise Option Scheme (EOS) which is for a duration of 10 years from 22 June 2015 and expiring on 21 June 2025. Brief details on the numbers of EOS options granted, exercised and outstanding since the commencement of the EOS until FY2023 are as follows: In accordance with the Bye Laws for the EOS, the total number of shares which may be issued under the EOS to eligible participants, including Executive Directors and Senior Management of the Company, shall not exceed the aggregate of 2% of our Company’s total number of issued shares. Additionally, the total number of shares which may be issued under EOS options granted to a participant, who either singly or collectively with persons connected with him or her owns 20% or more of the total number of issued shares of our Company, shall not exceed in aggregate 10% of the total number of shares to be issued under the EOS. None of our Directors and Senior Management, either singly or collectively with persons connected with them, owns 20% or more of the total number of issued shares of our Company. For FY2023, the actual percentage of EOS options granted to Senior Management of the Company was 10% of the total number of EOS options granted in 2023. No EOS options were granted to the Directors. Since the commencement of the EOS, the actual percentage of EOS options granted in aggregate to Executive Directors and Senior Management of the Company are 44% of the total number of EOS options granted. There were no EOS options granted to the Non-Executive Directors since the commencement dates of the EOS until FY2023. Details of the EOS options exercised during the financial year are disclosed in Note 21 of the financial statements. EOS Total number of EOS options granted 93,826,000 Total number of EOS options exercised 28,951,000 Total number of EOS options lapsed/cancelled/opted out 29,013,000 Total number of EOS options outstanding 35,862,000 Granted to Directors and Chief Executive EOS Aggregate number of EOS options granted 37,086,000 Aggregate number of EOS options exercised 26,930,000 Total number of EOS options lapsed/cancelled/opted out 6,105,000 Aggregate number of EOS options outstanding 4,051,000 Note: Includes the EOS options granted to Directors and Chief Executive who have left our Company/our Group. IHH Healthcare Berhad 122 Other Information Additional Compliance Information
RkJQdWJsaXNoZXIy NDgzMzc=